Dear Colleagues,

Cardiovascular disease has been the leading cause of death in the Western world.

Recent advances in pharmacotherapy, coupled with the marked improvement in interventional therapy in patients with coronary heart disease and acute myocardial infarction (e.g., primary PCI), have significantly improved the prognosis of patients with ischemic heart disease.

Nevertheless, the aging of population and the evolution of interventional techniques have brought about a revolution in the treatment of patients with structural heart disease.

The replacement of stenotic and calcified aortic valves is currently being done mostly by interventional procedures. In addition, there are many innovations and start-ups that aim to replace or repair the mitral and tricuspid valves. At the same time, there are marked developments with other structural problems such as closing interatrial or interventricular shunts (ASDs or VSDs), left atrial appendage occlusions in patients with AF that cannot accept anticoagulants, closing paravalvular leaks, etc. Recently, with the growing number of patients with heart failure, there are new interventional techniques for supporting the heart, creating new interatrial shunts etc.

On the other side, the COVID-19 pandemic has greatly contributed to the digital health revolution. Patients today can be followed 24/7 concerning their vital parameters such as blood pressure, heart rate and arrhythmias, oxygen saturation, respiratory rate, etc. These data can be directly sent to the cloud, and using AI (artificial intelligence) the patient and their doctor can get immediate alerts on the patient’s condition and intervene in order to avoid deterioration. In the future, digital revolution and new technology such as advanced analytics, machine learning, and augmented intelligence might change the process of innovation.

Given the complexity of this topic and its impact on clinical practice and public health, Medicina is launching a Special Issue entitled “Innovation in Cardiovascular Interventions” with the aim of presenting an update of current innovations as well as remaining unmet needs in order to develop new solutions.

Prof. Dr. Chaim Lotan
Guest Editor

Prof. Dr. Rafael Beyar
co-Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• aortic valve disease
• mitral valve disease
• digital health
• cardiovascular interventions
• cardiovascular innovation
• telemedicine
• structural heart disease
• peripheral vascular disease